JNJ - Johnson & Johnson
Pre-Market:
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 158.18 |
| Open | 158.10 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1400 |
| Day's Range | 157.44 - 158.80 |
| 52 Week Range | 150.11 - 183.35 |
| Volume | |
| Avg. Volume | 7,212,052 |
| Market Cap | 411.951B |
| Beta (5Y Monthly) | 0.53 |
| PE Ratio (TTM) | 33.16 |
| EPS (TTM) | 4.78 |
| Earnings Date | Jul 20, 2023 |
| Forward Dividend & Yield | 4.76 (3.01%) |
| Ex-Dividend Date | May 22, 2023 |
| 1y Target Est | 179.71 |
Fair Value
Related Research
ZacksAlkermes (ALKS) Gets Final Award in Janssen Arbitration, Ups View
Alkermes (ALKS) receives final award in arbitration proceedings with partner Janssen. It also raises its financial outlook for 2023.
Insider MonkeyTop 16 Dividend Stocks To Buy According To Hedge Funds
In this article, we will discuss top 16 dividend stocks to buy according to hedge funds. You can skip our detailed analysis of dividend stocks and their performance, and go directly to read Top 5 Dividend Stocks To Buy According To Hedge Funds. Dividends can be a significant component of hedge funds’ overall investment strategy […]
Motley Fool3 No-Brainer Stocks to Buy With $300 Right Now
A reasonably small amount of money can go a long way when it's invested in industry-leading businesses.
Business WireJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results
NEW BRUNSWICK, N.J., June 06, 2023--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Thursday, July 20th to review second-quarter results. Joaquin Duato, Chairman of the Board and CEO, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call.
BenzingaAlkermes Raises FY23 Outlook Following Arbitration Award from Janssen Agreements
Alkermes plc (NASDAQ: ALKS) increased its FY23 outlook by $425 million to reflect a final award the company received from arbitration proceedings related to two licensing agreements with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson (NYSE: JNJ). The updated guidance reflects the payment of back royalties of ~$194 million related to 2022 U.S. net sales of the long-acting Invega products and Cabenuva and anticipated royalty revenues related to 2023 sales. "We are gratified to have
BloombergTylenol Maker Kenvue Goes From Sure Bet to Question Mark After Year’s Biggest IPO
(Bloomberg) -- Kenvue Inc. looked like a winner following its May spinoff from Johnson & Johnson in the year’s biggest IPO. But just a few weeks after the stock’s initial surge, Wall Street is urging investors to avoid the shares.Most Read from BloombergPGA Tour Bows to Saudi Rival in Shock Combination With LIV GolfUkraine Dam Blast Blamed on Russia Tips War Into New PhaseGeorge Santos Loses Bid to Shield the People Who Guaranteed His $500,000 BailSEC’s Coinbase Lawsuit Heralds Deepening US Cryp
Insider Monkey20 Most Respected Professions in the World
This article covers the 20 most respected professions in the world. It will also explore the emerging trends in professions worldwide and the key players making a difference at the global level for various professions. If you want to skip our detailed analysis on the topic, you can head straight to the 5 Most Respected […]
ZacksJohnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
Johnson & Johnson (JNJ) closed at $158.32 in the latest trading session, marking a +0.86% move from the prior day.
Insider Monkey25 S&P 500 Dividend Aristocrats To Avoid
In this article, we discuss 25 dividend aristocrats to avoid according to hedge funds. You can skip our detailed analysis of dividend stocks and their performance, and go directly to read 10 S&P 500 Dividend Aristocrats To Avoid. Over the years, there has been an observable shift in focus from growth stocks to dividend stocks […]
ReutersAnalysis-Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast
Johnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the drug a larger contributor to J&J’s 2024 and 2025 sales than Wall Street is forecasting. Stelara, introduced in 2009, has been J&J’s top-selling drug since 2019, with sales reaching $9.7 billion in 2022. Its patents begin to expire this year, opening the door to a cheaper biosimilar entering the market, and raising expectations that the company would need to lower the $13,000 per month price of Stelara.
Insider Monkey10 Dementia Medications that are Approved or in Clinical Trials
In this article, we will be taking a look at the 10 dementia medications that are approved or in clinical trials. To skip our detailed analysis, you can go directly to see the 5 dementia medications that are approved or in clinical trials. Advancements in medicine have absolutely changed the way we live right now, […]
Motley Fool2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip
Dividend Kings are among the most steady corporations on the market. While many businesses don't even last a decade, these companies have survived and thrived and raised their payouts for at least 50 consecutive years to become a member of this elite group. Case in point: Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) are two members of this prominent clique that have lagged the market recently, partly due to company-specific concerns.
Motley Fool1 Ultra-Elite Dividend Stock to Buy Hand Over Fist in June
Johnson & Johnson (NYSE: JNJ) is one of the best dividend stocks on the planet. The healthcare behemoth has increased its dividend each year for over six decades, putting it in the super-elite class of Dividend Kings. The company currently offers a roughly 3% dividend yield, which is almost double that of an S&P 500 Index Fund (recently around 1.6%).
Motley Fool2 Warren Buffett Stocks to Buy in June and Hold Forever
These time-tested businesses produce reliable cash flows that they're committed to sharing with investors.
Motley FoolThe Little-Known Secret to Beating the S&P 500
If you can't beat the S&P 500 by picking individual stocks, owning an S&P 500 index fund and at least earning market returns is a smart move. Not just any dividend-paying stocks, mind you, but those that can grow their dividend payments consistently. Hartford Funds and Ned Davis Research have been tracking the average annual total returns of companies in the S&P 500 by dividend policy.
Simply Wall St.With 65% ownership, Johnson & Johnson (NYSE:JNJ) boasts of strong institutional backing
Key Insights Significantly high institutional ownership implies Johnson & Johnson's stock price is sensitive to their...
Motley FoolTwo Dow Stocks to Buy in June and Hold for the Next Decade
These two stocks look like the best options among the Dow Jones Industrial Average's 30 components right now.
Insider MonkeyS&P 500 Dividend Aristocrats List: Sorted By Hedge Fund Popularity
In this article, we will discuss the best dividend aristocrat stocks sorted by hedge fund popularity. You can skip our detailed analysis of dividend aristocrats and their past performance, and go directly to read S&P 500 Dividend Aristocrats List: Top 10 Among Hedge Funds. Dividend aristocrats are companies in the S&P 500 that have a […]
Insider Monkey14 Best Annual Dividend Stocks To Buy Now
In this article, we discuss 14 best annual dividend stocks to buy now. You can skip our detailed analysis of dividend stocks and their performance over the years, and go directly to read 5 Best Annual Dividend Stocks To Buy Now. Dividend stocks are garnering investors’ attention in 2023 as the stock market recovers from […]
ZacksLAVA (LVTX) Up on J&J's (JNJ) Cancer Study Candidate Selection
LAVA's (LVTX) shares soar as partner J&J (JNJ) selects a lead candidate for development in clinical studies for cancer.
Motley Fool3 High-Quality Dividend Stocks Yielding 3% to Buy in June
Many high-quality dividend stocks currently yield around 3%, nearly double that of the S&P 500. American Tower's dividend yield is currently over 3%, a historically high rate for the data-infrastructure real estate investment trust (REIT). The company has an exceptional track record of paying dividends.
- Reuters
UPDATE 1-J&J secures dismissal of whistleblower case over misuse of confidential info
A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs' misuse of confidential records they obtained through related litigation. The lawsuit, which accused J&J's DePuy Orthopaedics unit of defrauding the federal government by marketing defective hip implants, was dismissed in December 2021. J&J has denied wrongdoing.
ReutersJ&J secures dismissal of whistleblower case over misuse of confidential info
A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs' misuse of confidential records they obtained through related litigation. The lawsuit, which accused J&J's DePuy Orthopaedics unit of defrauding the federal government by marketing defective hip implants, was dismissed in December 2021. J&J has denied wrongdoing.
- Reuters
REFILE-J&J secures dismissal of whistleblower case over misuse of confidential info
A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs' misuse of confidential records they obtained through related litigation. The lawsuit, which accused J&J's DePuy Orthopaedics unit of defrauding the federal government by marketing defective hip implants, was dismissed in December 2021. J&J has denied wrongdoing.
InvestorPlace3 Warren Buffett Stocks to Buy (and Never Sell)
Many investors are looking for predictable and safe retirement stocks to buy. They want something sturdy, dependable and that (preferably) pays some sort of dividend. More than that, they want a business that they know and understand, and one that they are confident will have longevity. Those are the best stocks to own for a peaceful retirement. Of course, this completely varies by the investor, especially these days. Some investors simply want to collect a reliable dividend while the stock enjo
